for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Agios Pharmaceuticals Inc

AGIO.O

Latest Trade

60.46USD

Change

0.00(-0.00%)

Volume

1,531,235

Today's Range

59.08

 - 

60.83

52 Week Range

32.47

 - 

60.83

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Agios Shareholders Approve Sale Of Oncology Business To Servier

March 25 (Reuters) - Agios Pharmaceuticals Inc <AGIO.O>::AGIOS SHAREHOLDERS APPROVE SALE OF ONCOLOGY BUSINESS TO SERVIER.AGIOS PHARMACEUTICALS INC - BOARD OF DIRECTORS AUTHORIZED REPURCHASE OF UP TO $1.2 BILLION OF ITS OUTSTANDING SHARES AFTER CLOSE OF TRANSACTION.AGIOS PHARMACEUTICALS INC - EXPECTS TO CONDUCT SHARE REPURCHASES OVER NEXT 12-18 MONTHS.

Agios Submits Supplemental New Drug Application To FDA For Tibsovo (Ivosidenib Tablets) For Patients With Previously Treated Idh1-Mutant Cholangiocarcinoma

March 1 (Reuters) - Agios Pharmaceuticals Inc <AGIO.O>::AGIOS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO FDA FOR TIBSOVO® (IVOSIDENIB TABLETS) FOR PATIENTS WITH PREVIOUSLY TREATED IDH1-MUTANT CHOLANGIOCARCINOMA.AGIOS PHARMACEUTICALS - CO HAS REQUESTED PRIORITY REVIEW FOR APPLICATION OF TIBSOVO, WHICH, IF GRANTED, COULD RESULT IN A SIX-MONTH REVIEW PROCESS.

Agios Reports Fourth Quarter And Full Year 2020 Financial Results

Feb 25 (Reuters) - Agios Pharmaceuticals Inc <AGIO.O>::AGIOS REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS.AGIOS - OUTLINES PIVOTAL DEVELOPMENT PROGRAM FOR MITAPIVAT IN SICKLE CELL DISEASE, ENABLING A POTENTIAL BROAD LABEL BY YEAR-END 2026.AGIOS PHARMACEUTICALS INC QTRLY LOSS PER SHARE $1.41.AGIOS PHARMACEUTICALS INC QTRLY TOTAL REVENUE $44 MILLION VERSUS $35.4 MILLION.AGIOS - EXPECTS CASH, EQUIVALENTS, MARKETABLE SECURITIES WITH ANTICIPATED PRODUCT, ROYALTY REVENUE , AMONG OTHERS TO FUNDING EXPENSES TO 2022 END.

Agios Announces Phase 3 Activate-T Trial Of Mitapivat Achieved Primary Endpoint In Adults With Pyruvate Kinase Deficiency Who Are Regularly Transfused

Jan 26 (Reuters) - Agios Pharmaceuticals Inc <AGIO.O>::AGIOS ANNOUNCES PHASE 3 ACTIVATE-T TRIAL OF MITAPIVAT ACHIEVED PRIMARY ENDPOINT IN ADULTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED.AGIOS PHARMACEUTICALS INC - SAFETY PROFILE CONSISTENT WITH PREVIOUSLY REPORTED DATA.AGIOS PHARMACEUTICALS INC - 22 PERCENT OF PATIENTS TREATED WITH MITAPIVAT WERE TRANSFUSION-FREE DURING 24-WEEK FIXED DOSE PERIOD.AGIOS - EXPECTS TO FILE FOR REGULATORY APPROVAL FOR MITAPIVAT FOR TREATMENT OF ADULTS WITH PYRUVATE KINASE DEFICIENCY IN U.S. IN Q2, IN EU IN MID-2021.

Agios Presents Final Data From Phase 3 Claridhy Study Of Tibsovo® (Ivosidenib Tablets) In Patients With Previously Treated Idh1-Mutant Cholangiocarcinoma

Jan 17 (Reuters) - Agios Pharmaceuticals Inc <AGIO.O>::AGIOS PRESENTS FINAL DATA FROM PHASE 3 CLARIDHY STUDY OF TIBSOVO® (IVOSIDENIB TABLETS) IN PATIENTS WITH PREVIOUSLY TREATED IDH1-MUTANT CHOLANGIOCARCINOMA.AGIOS- FINAL ANALYSIS SHOWED IMPROVEMENT IN SECONDARY ENDPOINT OF OS FAVORING PATIENTS RANDOMIZED TO TIBSOVO VERSUS THOSE RANDOMIZED TO PLACEBO.HOWEVER, STATISTICAL SIGNIFICANCE WAS NOT REACHED.SAFETY PROFILE OBSERVED IN STUDY WAS CONSISTENT WITH PREVIOUSLY PUBLISHED DATA..

Agios Pharmaceuticals Says Pivotal Trials For Mitapivat In Thalassemia On Track For 2H 2021 Start

Jan 11 (Reuters) - Agios Pharmaceuticals Inc <AGIO.O>::AGIOS PHARMACEUTICALS INC - PIVOTAL TRIALS FOR MITAPIVAT IN THALASSEMIA ON TRACK FOR INITIATION IN 2H 2021 AND IN SICKLE CELL DISEASE BY YEAR-END.AGIOS PHARMACEUTICALS INC - SALE OF ONCOLOGY PORTFOLIO TO SERVIER EXPECTED TO CLOSE IN Q2 2021.AGIOS PHARMACEUTICALS INC - FULL-YEAR NET PRODUCT REVENUE FOR TIBSOVO IS EXPECTED TO BE $160-170 MILLION.AGIOS PHARMACEUTICALS - FOLLOWING COMPLETION OF SERVIER DEAL, AGIOS EXPECTS CASH RUNWAY TO EXTEND TO CASH-FLOW POSITIVITY IN 2025.

Agios Pharmaceuticals To Sell Oncology Business To Servier For Up To $2 Billion Plus Royalties

Dec 21 (Reuters) - AGIOS PHARMACEUTICALS: :AGIOS PHARMACEUTICALS - TO FOCUS ON DEVELOPING AND COMMERCIALIZING TREATMENTS FOR GENETICALLY DEFINED DISEASES.AGIOS PHARMACEUTICALS - TO SELL ONCOLOGY BUSINESS TO SERVIER FOR UP TO $2 BILLION PLUS ROYALTIES.AGIOS PHARMACEUTICALS - DEAL INCLUDES RECEIPT OF $1.8 BILLION IN UPFRONT CASH, POTENTIAL $200 MILLION REGULATORY MILESTONE PAYMENT & FUTURE ROYALTIES.AGIOS PHARMACEUTICALS - DEAL INCLUDES TRANSFER OF CO'S ONCOLOGY PORTFOLIO, INCLUDING MARKETED MEDICINE TIBSOVO.AGIOS PHARMACEUTICALS - SERVIER WILL ALSO ACQUIRE CO'S CO-COMMERCIALIZATION RESPONSIBILITIES FOR BRISTOL MYERS SQUIBB’S IDHIFA.AGIOS PHARMACEUTICALS - DEAL INCLUDES CO'S ONCOLOGY PIPELINE AND CLINICAL PROGRAMS, INCLUDING VORASIDENIB.AGIOS PHARMACEUTICALS - PLANS TO RETURN AT LEAST $1.2 BILLION TO SHAREHOLDERS FOLLOWING DEAL CLOSE.

Agios Announces Updated Data From Phase 1 Study Of Mitapivat, First-In-Class Pkr Activator, In Sickle Cell Disease

Dec 7 (Reuters) - Agios Pharmaceuticals Inc <AGIO.O>::AGIOS ANNOUNCES UPDATED DATA FROM PHASE 1 STUDY OF MITAPIVAT, FIRST-IN-CLASS PKR ACTIVATOR, IN SICKLE CELL DISEASE.AGIOS PHARMACEUTICALS - SAFETY PROFILE GENERALLY CONSISTENT WITH PREVIOUSLY PRESENTED DATA IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY AND THALASSEMIA.AGIOS PHARMACEUTICALS INC - DATA SUPPORT ADVANCEMENT OF MITAPIVAT TO PIVOTAL DEVELOPMENT IN SICKLE CELL DISEASE.AGIOS PHARMACEUTICALS INC - COMPANY EXPECTS TO INITIATE PIVOTAL PROGRAM IN 2021.

Agios Announces The Phase 3 Activate Trial Of Mitapivat Achieved Its Primary Endpoint In Adults With Pyruvate Kinase Deficiency Who Are Not Regularly Transfused

Dec 1 (Reuters) - Agios Pharmaceuticals Inc <AGIO.O>::AGIOS ANNOUNCES THE PHASE 3 ACTIVATE TRIAL OF MITAPIVAT ACHIEVED ITS PRIMARY ENDPOINT IN ADULTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED.AGIOS PHARMACEUTICALS INC - 40 PERCENT OF PATIENTS TREATED WITH MITAPIVAT ACHIEVED A SUSTAINED HEMOGLOBIN INCREASE OF ≥1.5 G/DL.AGIOS PHARMACEUTICALS INC - SAFETY PROFILE CONSISTENT WITH PREVIOUSLY REPORTED DATA.AGIOS PHARMACEUTICALS INC - TOPLINE DATA FROM MITAPIVAT PHASE 3 ACTIVATE-T TRIAL IN REGULARLY TRANSFUSED PK DEFICIENCY EXPECTED IN Q1 2021.AGIOS PHARMACEUTICALS INC - TREATMENT WITH MITAPIVAT DEMONSTRATED STATISTICALLY SIGNIFICANT IMPROVEMENTS ACROSS PRE-SPECIFIED KEY SECONDARY ENDPOINTS.AGIOS PHARMACEUTICALS INC - ANTICIPATES FILING FOR U.S. AND EU REGULATORY APPROVAL IN ADULTS WITH PK DEFICIENCY IN 2021.

Agios Reports FDA Orphan Drug Designation Granted To Mitapivat

Nov 12 (Reuters) - Agios Pharmaceuticals Inc <AGIO.O>::AGIOS ANNOUNCES FDA ORPHAN DRUG DESIGNATION GRANTED TO MITAPIVAT FOR TREATMENT OF SICKLE CELL DISEASE.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up